These regimens aim to remodel the tumor microenvironment—enhancing antigen presentation, elevating T-cell infiltration, and up-regulating checkpoint ligands—thereby augmenting the response to PD-1/PD-L1 or CTLA-4 inhibitors. The gene discussed is PDCD1; the disease is neoplasm.